2011/12 Tender Consultation - Medical Groups (text extract)

This is the text extract for 2011/12 Tender Consultation - Medical Groups, browse documents here.

11 July 2011

2011/12 Multi-product Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:   A proposal to tender certain pharmaceuticals for sole supply; and The draft process and terms and conditions for the 2011/12 Invitation to Tender.

PHARMAC welcomes all feedback on the 2011/12 Invitation to Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and would be considered by the PHARMAC Board (or Chief Executive acting under Delegated Authority) prior to making a decision on this proposal.

ALL RESPONSES ARE DUE BY 5PM, FRIDAY 19 AUGUST 2011

Feedback should be provided by submitting an email, fax or letter to: Kyle Reid Tender Analyst PHARMAC PO Box 10-254 Wellington 6143 Email: kyle.reid@pharmac.govt.nz Fax: (04) 460 4995 DDI: (04) 916 7556

Details of the proposed 2011/12 multi-product tender In accordance with PHARMAC’s objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies. Attached to this letter (as Schedule One) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a ‘C’ and/or ‘H’ next to it to indicate whether it is proposed to be tendered for community and/or hospital supply. In general, the proposed Tender process would be similar to the 2010/11 Tender. A copy of the draft 2011/12 Invitation to Tender is available on our website: www.pharmac.govt.nz, or by contacting PHARMAC. We are seeking feedback on the approach outlined in the following pages, in particular on:  The proposed tender process and timeline;

A424769 - qA21977



The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One, including the impact of a brand switch on patients and clinical staff; and For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.



Background Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different. Key Aspects of Awarding a Tender for Community Pharmaceuticals:  For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2015 for all Tenders awarded from the 2011/12 Invitation to Tender. No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period. Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy. Any pharmaceutical that currently carries a manufacturer’s surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

  

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:  For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2015 for all tenders awarded from the 2011/12 Invitation to Tender. No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.



Tender Timelines This year we are proposing similar timelines to the 2010/11 Tender. In 2011, this has allowed us to consider and award bids earlier, giving the market and suppliers more notice of brand changes to better inform stock management. The proposed timelines for the 2011/12 Tender are as follows:

Date 11 July 2011 05 August 2011 19 August 2011 Event Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for receipt of Alternative Commercial Proposals (ACPs) from suppliers by PHARMAC. Final date for all consultation to be received.

A424769 - qA21977

05 September 2011

Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC’s Decision Criteria and enters into provisional contracts with suppliers where appropriate. Consultation and Board decisions on Alternative Commercial Proposals. 2011/12 Invitation to Tender issued. Invitation to Tender closes. Board decisions on the first Tender winners announced.

September 2011 September/October 2011 Early November 2011 21 December 2011 From end of January 2012

Contractual obligations for suppliers A copy of the draft terms and conditions which would form the terms of the 2011/12 Tender contract is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50. Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from 2009/10 Tender and the 2010/11 Tender prior to issuing the 2011/12 Invitation to Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider including those pharmaceuticals in the 2011/12 Invitation to Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule One. Distribution of Consultation Documents Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at www.pharmac.govt.nz/consultation). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter. Tender items subject to Special Authority criteria We are proposing to allow bids for both the current access criteria and for widened access criteria (e.g. with no Special Authority (SA) criteria) for some products currently subject to SA restrictions. In previous tenders suppliers have indicated that they may be able to offer better pricing if they have certainty that SA criteria would be removed following a tender being awarded. Allowing bids for both levels of access would mean that suppliers would be able to offer their best pricing for both access levels. If we did proceed with this approach in the 2011/12 Tender, only one option would be awarded (i.e. for either the current access criteria or widened access criteria), although, PHARMAC would retain the discretion to subsequently widen access at a later date if the tender were awarded for the current access criteria. The removal of SA criteria may be subject to PHARMAC taking clinical advice on the appropriateness of removing criteria. Examples of products where we are considering allowing bids under both the current access criteria and widened access criteria are capecitabine, irinotecan and vinorelbine, included in Schedule Two of the draft 2011/12 Tender.

A424769 - qA21977 3

Schedule One: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

Therapeutic Group Alimentary Tract and Metabolism Blood and Blood Forming Organs Cardiovascular System Dermatologicals Genito-Urinary System Hormone Preparations – Systemic excluding contraceptives Infections – Agents for Systemic Use Musculoskeletal System Nervous System Oncology and Immunosuppressants Respiratory System and Allergies Sensory Organs Page Numbers 6-7 7-8 8-9 9 – 11 11 11 - 12 12 – 14 14 15 - 18 18 – 21 21 - 22 22 - 23

Information provided for each pharmaceutical For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:    the current ex-manufacturer subsidy per unit of measure as at 1 July 2011; the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2011*. an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2011 by the relevant listed unit subsidy as at 1 July 2011); and comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.



* The market data for the year ended 30 June 2011 provided has not yet been finalised; however, finalised

data would be captured in the final 2011/12 Tender.

A424769 - qA21977

Explanation of terms, symbols and abbreviations Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed. The following table explains the symbols used in the draft pharmaceutical list:

Symbol Underlined C H PCT + * Explanation Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2012 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date. To be tendered for Sole Subsidised Supply Status (community pharmaceuticals). To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals). A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project. PHARMAC has been advised of the existence of a patent. There is no fully funded product available for this line item (in relation to community supply).

A424769 - qA21977

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Units Cost Unit Subsidy DV Limit Comments

Alimentary Tract and Metabolism

Acarbose Tab 50 mg Tab 100 mg Atropine Sulphate Inj 600 mcg, 1 ml Calcitriol Cap 0.25 mcg Cap 0.5 mcg Chlorhexidine gluconate Mouthwash 0.2% Cholecalciferol Tab 1.25 mg (50,000 iu) Glipizide Tab 5 mg Glycerol Suppos greater than 3 g Hydrocortisone Acetate Rectal foam 10%, CFC-free Hydroxocobalamin Inj 1 mg per ml, 1 ml Lansoprazole Cap 15 mg 1,138,500 $142,313 $0.1250 C H 1%

A tender would not be implemented prior to September 2012 A tender would not be implemented prior to September 2012

1,349,106 419,055

$247,336 $124,320

$0.1833 $0.2967

C H C H

1% 1%

64,736

$67,325

$1.0400

C H

1,992,104 462,894

$201,203 $86,715

$0.1010 $0.1873

C H C H

1% 1%

2,596,854

$50,249

$0.0194

C H

2,015,516

$1,303,367

$0.6467

C H

14,523,763

$508,332

$0.0350

C H

223,766

$67,130

$0.3000

C H

206,440

$225,029

$1.0900

C H

260,669

$534,371

$2.0500

C H

Cap 30 mg

3,049,230

$506,390

$0.1661

C H

L-Carnitine Inj 200 mg per ml C H 1%

Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria. Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria. Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria. Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.

Oral liquid 500 mg per 15 ml

C H

Powder

C H

Tab 300 mg - 500 mg

C H

Mesalazine Enema 1 g per 100 ml 54,805 $359,834 $6.5657 C H 1% 6

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Mesalazine Tab EC 500 mg Metformin Hydrochloride Tab immediate-release 500 mg Tab immediate-release 850 mg Miconazole Oral gel 20 mg per g Pioglitazone Tab 15 mg Tab 30 mg Tab 45 mg 544,130 468,410 400,807 $50,721 $87,492 $111,653 $0.0932 $0.1868 $0.2786 C H C H C H 1% 1% 1% 637,292 $138,611 $0.2175 C H 1% 91,290,791 16,607,503 $1,477,085 $443,088 $0.0162 $0.0267 C H C H 1% 1% 148,439 $73,477 $0.4950 C H 1% Units Cost Unit Subsidy DV Limit Comments

Blood and Blood Forming Organs

Atorvastatin Tab 10 mg 8,169,186 $4,988,650 $0.6107 C H 1%

Confiedntial rebate exists. A tender would not be implemented prior to 1 June 2012. Confiedntial rebate exists. A tender would not be implemented prior to 1 June 2012. Confiedntial rebate exists. A tender would not be implemented prior to 1 June 2012. Confiedntial rebate exists. A tender would not be implemented prior to 1 June 2012.

Tab 20 mg

13,404,512

$11,930,016

$0.8900

C H

Tab 40 mg

13,912,170

$17,167,618

$1.2340

C H

Tab 80 mg

1,985,589

$7,313,586

$3.6833

C H

Bezafibrate Tab 200 mg Tab long-acting 400 mg Enoxaparin Sodium Inj 20 mg per 0.2 ml Inj 40 mg per 0.4 ml Inj 60 mg per 0.6 ml Inj 80 mg per 0.8 ml Inj 100 mg per ml, 1 ml Inj 120 mg per 0.8 ml Inj 150 mg per ml, 1 ml Heparin Sodium Inj 100 iu per ml, 250 ml Heparinised Saline Inj 100 iu per ml, 2 ml ampoule Inj 100 iu per ml, 5 ml ampoule H H 1% 1% 7 H 1% 6,812 70,735 28,422 44,855 58,482 35,337 21,582 $26,703 $369,944 $224,107 $471,516 $790,677 $593,662 $414,374 $3.9200 $5.2300 $7.8850 $10.5120 $13.5200 $16.8000 $19.2000 C H C H C H C H C H C H C H 1% 1% 1% 1% 1% 1% 1% 1,161,894 6,349,031 $125,872 $1,206,316 $0.1083 $0.1900 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Hydroxyethyl Starch 130/0.4 Inj 6% Hydroxyethyl Starch 200/0.5 Inj 6% Potassium Chloride Tab long-acting 600 mg Tranexamic Acid Inj 100 mg per ml, 5 ml H 1% 10,235,670 $358,248 $0.0350 C H 1% H 1% H 1% Units Cost Unit Subsidy DV Limit Comments

Cardiovascular System

Atenolol Tab 50 mg Tab 100 mg Clonidine Inj 150 mcg per ml, 1 ml Tab 25 mcg Tab 150 mcg TDDS 2.5 mg, 100 mcg per day TDDS 5 mg, 200 mcg per day TDDS 7.5 mg, 300 mcg per day Diltiazem Hydrochloride Tab 30 mg Tab 60 mg Cap long-acting 120 mg Cap long-acting 180 mg Cap long-acting 240 mg Enalapril Tab 5 mg Tab 10 mg Tab 20 mg Felodipine Tab long-acting 2.5 mg Tab long-acting 5 mg Tab long-acting 10 mg Furosemide Tab 40 mg Tab 500 mg Glyceryl Trinitrate Inj 1 mg per ml, 5 ml H 1% 8 36,605,391 246,100 $393,508 $123,050 $0.0108 $0.5000 C H C H 1% 1% 9,453,744 15,941,345 11,509,413 $3,270,995 $1,900,563 $1,994,965 $0.3460 $0.1192 $0.1733 C H C H C H 1% 1% 1% 3,562,631 3,524,700 3,394,992 $78,378 $95,559 $122,220 $0.0220 $0.0271 $0.0360 C H C H C H 1% 1% 1% 641,943 365,906 8,735,834 7,447,403 5,283,655 $29,529 $31,102 $1,264,075 $1,613,852 $1,526,976 $0.0460 $0.0850 $0.1447 $0.2167 $0.2890 C H C H C H C H C H 1% 1% 1% 1% 1% 10,798 2,654,960 539,110 46,088 13,059 9,436 $33,366 $511,080 $177,906 $268,463 $107,084 $97,191 $3.0900 $0.1925 $0.3300 $5.8250 $8.2000 $10.3000 C H C H C H C H C H C H 1% 1% 1% 1% 1% 1% 6,949,334 2,704,806 $85,894 $58,045 $0.0124 $0.0215 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Glyceryl Trinitrate Inj 1 mg per ml, 50 ml Inj 5 mg per ml, 10 ml Lisinopril Tab 5 mg Tab 10 mg Tab 20 mg Nadolol Tab 40 mg Tab 80 mg Pindolol Tab 5 mg Tab 10 mg Tab 15 mg Sotalol Tab 80 mg Tab 160 mg Timolol Maleate Tab 10 mg 138,978 $14,662 $0.1055 C H 1% 4,109,964 358,745 $226,048 $37,668 $0.0550 $0.1050 C H C H 1% 1% 227,995 256,327 105,971 $12,312 $23,556 $14,624 $0.0540 $0.0919 $0.1380 C H C H C H 1% 1% 1% 1,962,348 620,894 $293,763 $137,776 $0.1497 $0.2219 C H C H 1% 1% 823,657 887,820 1,199,797 $56,558 $69,842 $114,781 $0.0687 $0.0787 $0.0957 C H C H C H 1% 1% 1% H H 1% 1% Units Cost Unit Subsidy DV Limit Comments

Dermatologicals

Betamethasone Valerate Scalp app 0.1% Calamine Crm, aqueous, BP Lotn, BP Calcipotriol Crm 50 mcg per g (pack size 30 g or less) Crm 50 mcg per g (pack size greater than 30 g) Oint 50 mcg per g (pack size 30 g or less) Oint 50 mcg per g (pack size greater than 30 g) Soln 50 mcg per ml (pack size 30 ml or less) Soln 50 mcg per ml (pack size greater than 30 ml) Chlorhexidine Crm 1% obstetric Chlorhexidine Gluconate Handrub 0.5% - 1% with ethanol 70% 2,389,438 $21,983 $0.0092 C

Chlorhexidine strengths from 0.5% to 1% would be considered

2,894,313

$208,969

$0.0722

C H

902,615 5,205,621

$25,093 $43,467

$0.0278 $0.0084

C H C H

1% 1%

42,780 1,458,700 40,620 1,436,400 43,080 238,140

$28,805 $821,540 $27,351 $808,980 $29,036 $134,113

$0.6733 $0.5632 $0.6733 $0.5632 $0.6740 $0.5632

C H C H C H C H C H C H

1% 1% 1% 1% 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Ciclopiroxolamine Nail soln 8% Clobetasol Propionate Crm 0.05% (pack size 30 g or less) Oint 0.05% (pack size 30 g or less) Scalp app 0.05% Crotamiton Crm 10% Fluorouracil Sodium Crm 5% 554,491 $734,423 $1.3245 C H 1%

A tender would not be implemented prior to October 2012

Units

Cost

Unit Subsidy

DV Limit

Comments

80,403

$456,000

$5.6714

2,781,830 2,779,609 578,567

$322,692 $322,435 $122,656

$0.1160 $0.1160 $0.2120

C H C H C H

1% 1% 1%

560,138

$106,146

$0.1895

C H

Hydrocortisone Butyrate Lipocream 0.1% (pack size 30 g or less) 1,979,340 $151,749 $0.0767 C H 1%

A tender would not be implemented prior to November 2012 A tender would not be implemented prior to November 2012 Not currently listed on the Pharmaceutical Schedule. A tender would not be implemented prior to November 2012. A tender would not be implemented prior to November 2012 Not currently listed on the Pharmaceutical Schedule. A tender would not be implemented prior to November 2012. A tender would not be implemented prior to November 2012 A tender would not be implemented prior to November 2012

Lipocream 0.1% (pack size greater than 30 g)

17,313,700

$1,327,384

$0.0767

C H

Milky Emulsion 0.1% (pack size 30 g or less)

C H

Milky Emulsion 0.1% (pack size greater than 30 g) Oint 0.1% (pack size 30 g or less)

1,598,597

$109,504

$0.0685

C H

Oint 0.1% (pack size greater than 30 g)

1,938,341

$132,776

$0.0685

C H

Scalp lotn 0.1%

3,598,370

$131,341

$0.0365

C H

Hydrocortisone with Natamycin and Neomycin Crm 1% with natamycin 1% and neomycin sulphate 0.5% Oint 1% with natamycin 1% and neomycin sulphate 0.5% 2,302,991 $428,356 $0.1860 C H 1%

A tender would not be implemented prior to November 2012 A tender would not be implemented prior to November 2012

848,073

$157,742

$0.1860

C H

Isotretinoin Cap 10 mg 1,340,876 $361,143 $0.2693 C H 1%

Information on appropriate use should be available on a website Information on appropriate use should be available on a website

Cap 20 mg

1,403,423

$543,437

$0.3872

C H

Mometasone Furoate Crm 0.1% (pack size 30 g or less) 280,315 $44,477 $0.1587 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Mometasone Furoate Crm 0.1% (pack size greater than 30 g) Oint 0.1% (pack size 30 g or less) Oint 0.1% (pack size greater than 30 g) Oil in Water Emulsion Crm 57,990,643 $324,748 $0.0056 C H 1%

A tender would not be implemented until at least 1 August 2012.

Units

Cost

Unit Subsidy

DV Limit

Comments

2,810,260 173,760 1,940,106

$445,895 $27,570 $307,830

$0.1587 $0.1587 $0.1587

C H C H C H

1% 1% 1%

Paraffin White soft or yellow soft (pack size 30 g or less) H 1%

Genito Urinary System

Alprostadil Inj 0.5 mg per ml, 1 ml Intra-Uterine Device IUD - Short length IUD - Standard length 6,514 6,514 $257,303 $257,303 $39.5000 $39.5000 C H C H 1% 1%

Units aggregated for both lengths Units aggregated for both lengths

Norethisterone Tab 350 mcg Oxytocin Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Pregnancy Tests - HCG Urine Urine diagnostic test 425,767 $242,687 $0.5700 C H 1% 858 5,035 2,911 $1,019 $7,532 $5,892 $1.1880 $1.4960 $2.0240 C H C H C H 1% 1% 1% 10,338,814 $880,030 $0.0851 C

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Cabergoline Tab 0.5 mg Cyproterone Acetate Tab 50 mg Tab 100 mg Dexamethasone Tab 0.5 mg - 1 mg 419,267 $67,418 $0.1608 C H 1%

1 mg tablet units and subsidy shown. A 0.5 mg tablet is not currently listed in the Pharmaceutical Schedule.

62,400

$514,800

$8.2500

C H

805,460 35,188

$339,904 $29,206

$0.4220 $0.8300

C H C H

1% 1%

Tab 4 mg Ethinyloestradiol Tab 10 mcg

791,534

$489,880

$0.6189

C H

363,573

$63,989

$0.1760

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Gestrinone Cap 2.5 mg Hydrocortisone Tab 5 mg Tab 20 mg Methylprednisolone Tab 4 mg Tab 100 mg Methylprednisolone Acetate Inj 40 mg per ml, 1 ml Methylprednisolone Acetate with Lignocaine Inj 40 mg per ml with lignocaine 1 ml Methylprednisolone Sodium Succinate Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Prednisolone Sodium Phosphate Oral liq 5 mg per ml Testosterone Undecanoate Cap 40 mg 884,574 $706,952 $0.7992 C H 1% 3,865,171 $1,281,948 $0.3317 C H 1% 509 687 128 71 $3,083 $11,338 $2,662 $3,022 $6.0560 $16.5036 $20.8000 $42.5700 C H C H C H C H 1% 1% 1% 1% 2,148 $12,952 $6.0300 C H 1% 5,870 $35,396 $6.0300 C H 1% 31,408 22,794 $15,255 $189,783 $0.4857 $8.3260 C H C H 1% 1% 2,874,266 133,427 $240,001 $27,953 $0.0835 $0.2095 C H C H 1% 1% 4,575 $58,257 $12.7338 C H 1% Units Cost Unit Subsidy DV Limit Comments

Infections - Agents for Systemic Use

Aciclovir Cream 5% Inj 250 mg Amoxycillin Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Amoxycillin Clavulanate Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Inj 600 mg Inj 1.2 g Amphotericin B Liposomal inj 50 mg Azithromycin Tab 500 mg 107,799 $320,702 $2.9750 C H 1% 12 H 1% 10,232,449 $225,114 $0.0220 C H 1%

ASP

C H H

1% 1%

Not currently listed on the Pharmaceutical Schedule

29,649,920 28,276,430

$459,574 $311,041

$0.0155 $0.0110

C H C H

1% 1%

15,452,855

$594,935

$0.0385

C H

ASP

H H

1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Benzathine Benzylpenicillin Inj 1.2 mega u Caspofungin Inj 50 mg Inj 70 mg Cephalexin Monohydrate Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Co-Trimoxazole Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Efavirenz Cap 50 mg Cap 100 mg Cap 200 mg Tab 50 mg Tab 200 mg Tab 600 mg Emtricitabine Cap 200 mg Erythromycin Ethyl Succinate Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 400 mg Flucloxacillin Grans for oral liq 125 mg per 5 ml 6,209,212 $193,727 $0.0312 C H 1%

Bids would be accepted for either the sodium or magnesium salts Bids would be accepted for either the sodium or magnesium salts

Units

Cost

Unit Subsidy

DV Limit

Comments

7,200

$226,800

$31.5000

C H

ASP

H H

1% 1%

151,572 293,319

$12,884 $33,732

$0.0850 $0.1150

C H C H

1% 1%

3,324,816

$113,044

$0.0340

C H

+ C H + C H + C H

2,738 2,088 228,554 $14,450 $11,020 $3,618,695 $5.2777 $5.2777 $15.8330

1% 1% 1% 1% 1% 1%

+ C H + C H + C H

245,880

$2,517,811

$10.2400

+ C H

7,069,230 4,483,547 4,871,360

$307,512 $262,287 $825,696

$0.0435 $0.0585 $0.1695

C H C H C H

1% 1% 1%

ASP ASP

Grans for oral liq 250 mg per 5 ml

7,735,625

$274,615

$0.0355

C H

Flucloxacillin Sodium Cap 250 mg Cap 500 mg Fluconazole Inj 2 mg per ml, 50 ml Gentamicin Sulphate Inj 40 mg per ml, 2 ml Hydroxychloroquine Sulphate Tab 200 mg 2,860,868 $643,695 $0.2250 C H 1% 5,153 $4,638 $0.9000 C H 1% H 1% 1,593,425 11,035,657 $203,958 $2,427,845 $0.1280 $0.2200 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Isoniazid Tab 100 mg 240,528 $48,106 $0.2000 C H 1%

A tender would not be implemented prior to November 2012

Units

Cost

Unit Subsidy

DV Limit

Comments

Nevirapine Oral suspension 10 mg per ml Tab 200 mg Nitrofurantoin Oral liq 25 mg per 5 ml Tab 50 mg Tab 100 mg Ritonavir Cap 100 mg Oral liq 80 mg per ml Roxithromycin Tab 150 mg Tab 300 mg 2,511,083 941,935 $450,991 $310,462 $0.1796 $0.3296 C H C H 1% 1%

ASP ASP

10,993 167,750

$6,163 $894,108

$0.5606 $5.3300

C H C H

1% 1%

C H 1,795,060 566,769 $398,503 $212,538 $0.2220 $0.3750 C H C H

1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

90,389 0

$130,494 $0

$1.4437 $1.1553

+ C H + C H

1% 1%

Musculoskeletal System

Baclofen Inj 10 mg Tab 10 mg Diclofenac Sodium Tab EC 25 mg Tab EC 50 mg Tab long-acting 75 mg Tab long-acting 100 mg Etidronate Disodium Tab 200 mg Indomethacin Cap 25 mg Cap 50 mg Cap long-acting 75 mg C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

H 3,602,772 $171,132 $0.0475 C H

1% 1%

611,472 4,541,303 23,324,952 3,455,177

$19,934 $193,460 $1,530,117 $436,873

$0.0326 $0.0426 $0.0656 $0.1264

C H C H C H C H

1% 1% 1% 1%

1,117,632

$267,673

$0.2395

C H

Naproxen Tab 250 mg Tab 500 mg Quinine Sulphate Tab 300 mg 1,639,886 $177,304 $0.1081 C H 1% 1,933,579 4,364,536 $91,652 $434,359 $0.0474 $0.0995 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Units Cost Unit Subsidy DV Limit Comments

Nervous System

Aripiprazole Tab 10 mg Tab 15 mg Tab 20 mg Tab 30 mg Atracurium Besylate Inj 10 mg per ml, 2.5 ml Inj 10 mg per ml, 5 ml Bupivacaine Hydrochloride Inj 0.25%, 20 ml Inj 0.5%, 10 ml Inj 0.5%, 10 ml theatre pack Inj 0.5%, 20 ml theatre pack Clomipramine Hydrochloride Tab 10 mg Tab 25 mg Codeine Phosphate Tab 15 mg 5,434,686 $292,930 $0.0539 C H 1%

A tender would not be implemented prior to November 2012 A tender would not be implemented prior to November 2012 A tender would not be implemented prior to November 2012

H H H H

1% 1% 1% 1%

H H

1% 1%

H H H H

1% 1% 1% 1%

302,166 1,883,291

$38,073 $163,470

$0.1260 $0.0868

C H C H

1% 1%

Tab 30 mg

20,111,116

$1,659,167

$0.0825

C H

Tab 60 mg

1,942,316

$344,955

$0.1776

C H

Cyclizine Hydrochloride Tab 50 mg Dexamphetamine Sulphate Tab 5 mg 641,809 $105,898 $0.1650 C H 1%

A tender would not be implemented prior to November 2012

1,155,093

$183,660

$0.1590

C H

Donepezil hydrochloride Tab 5 mg Tab 10 mg 639,394 651,151 $54,775 $101,724 $0.0857 $0.1562 C H C H 1% 1%

Recently listed on Pharmaceutical Schedule Recently listed on Pharmaceutical Schedule

Dopamine Inj 40 mg per ml, 5 ml Doxepin Hydrochloride Cap 10 mg 1,660,537 $87,012 $0.0524 C H 1%

A tender would not be implemented until at least November 2012.

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Doxepin Hydrochloride Cap 25 mg 2,238,223 $122,207 $0.0546 C H 1%

A tender would not be implemented until at least November 2012. A tender would not be implemented until at least November 2012. Not currently listed. A tender would not be implemented until at least November 2012.

Units

Cost

Unit Subsidy

DV Limit

Comments

Cap 50 mg

932,297

$68,431

$0.0734

C H

Cap 75 mg

C H

Entacapone Tab 200 mg Fentanyl Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 10 ml Granisetron Tab 1 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

690,619

$801,118

$1.1600

C H

73,463 11,424

$47,237 $19,204

$0.6430 $1.6810

C H C H

1% 1%

Lignocaine Gel 2% Lignocaine Hydrochloride Inj 1%, 2 ml Inj 1%, 5 ml Inj 1%, 20 ml Inj 2%, 2 ml Inj 2%, 5 ml Inj 2%, 20 ml Lithium Carbonate Tab 250 mg Tab 400 mg Tab long-acting 400 mg Methadone Hydrochloride Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Mirtazapine Tab 15 mg Tab 30 mg Tab 45 mg 629,445 131,842 $461,572 $153,807 $0.7333 $1.1666 C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

H H H H H H

1% 1% 1% 1% 1% 1%

1,946,246 289,100 1,282,514

$140,519 $39,029 $237,265

$0.0722 $0.1350 $0.1850

C H C H C H

1% 1% 1%

1,852,661 23,246,976 3,408,625

$55,117 $645,104 $152,536

$0.0298 $0.0278 $0.0448

C H C H C H

1% 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Moclobemide Tab 150 mg Tab 300 mg Morphine Hydrochloride Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Morphine Sulphate Tab immediate release 10 mg Tab immediate release 20 mg Nortriptyline hydrochloride Oral liq 10 mg per 5 ml Tab 10 mg Tab 25 mg Ondansetron Hydrochloride Inj 2 mg per ml, 2 ml Inj 2 mg per ml, 4 ml Oxycodone Hydrochloride Cap 5 mg 1,986,372 $281,072 $0.1415 C H 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

1,322,067 396,647

$183,053 $124,270

$0.1385 $0.3133

C H C H

1% 1%

5,986,436 683,564 823,661 557,546

$264,600 $39,715 $60,333 $60,076

$0.0442 $0.0581 $0.0733 $0.1078

C H C H C H C H

1% 1% 1% 1%

1,556,437 678,780

$435,802 $374,687

$0.2800 $0.5520

C H C H

1% 1%

C H 6,550,532 8,297,885 $389,102 $665,675 $0.0594 $0.0802 C H C H

1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

H H

1% 1%

Cap 10 mg

1,264,947

$352,920

$0.2790

C H

Cap 20 mg

531,908

$259,837

$0.4885

C H

Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 2 ml Oral liq 5 mg per 5 ml Tab controlled-release 5 mg

35,454 53,872 1,480,024 1,200,966

$102,108 $310,303 $66,305 $450,963

$2.8800 $5.7600 $0.0448 $0.3755

C H C H C H C H

1% 1% 1% 1%

Product should be supplied in blister packs or bottle with child-resistant cap. Product should be supplied in blister packs or bottle with child-resistant cap. Product should be supplied in blister packs or bottle with child-resistant cap. Product should be supplied in blister packs or bottle with child-resistant cap. Product should be supplied in blister packs or bottle with child-resistant cap.

Tab controlled-release 10 mg

2,502,402

$1,393,838

$0.5570

C H

Tab controlled-release 20 mg

1,627,540

$1,540,467

$0.9465

C H

Tab controlled-release 40 mg

490,424

$816,311

$1.6645

C H

Tab controlled-release 80 mg

202,375

$587,191

$2.9015

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Pancuronium bromide Inj 2 mg per ml, 2 ml Paracetamol Suppos 500 mg 128,785 $52,802 $0.4100 C H 1%

A tender would not be implemented prior to November 2012

Units

Cost

Unit Subsidy

DV Limit

Comments

Pethidine Hydrochloride Tab 50 mg 244,205 $78,146 $0.3200 C H 1%

A tender would not be implemented prior to November 2012. Product should be supplied in blister packs or bottle with childresistant cap. A tender would not be implemented prior to November 2012. Product should be supplied in blister packs or bottle with childresistant cap.

Tab 100 mg

94,432

$39,661

$0.4200

C H

Phenobarbitone Oral liq 15 mg per 5 ml C H 1%

Not currently listed on the Pharmaceutical Schedule. Alcohol free preparation preferred. A tender would not be implemented prior to November 2012 A tender would not be implemented prior to November 2012

Tab 15 mg

93,678

$4,684

$0.0500

C H

Tab 30 mg

698,500

$36,322

$0.0520

C H

Phenobarbitone Sodium Inj 200 mg per ml, 1 ml Pizotifen Tab 500 mcg Rocuronium Inj 10 mg per ml, 5 ml Selegiline Hydrochloride Tab 5 mg Tropisetron Cap 5 mg Inj 1 mg per ml, 2 ml 2,041 $31,599 $15.4820 C H H 1% 1% 190,971 $30,670 $0.1606 C H 1% 1,357,566 $286,446 $0.2110 C H 1% H 1%

Oncology Agents and Immunosuppressants

Capecitabine (current access) Tab 150 mg 688,630 $4,045,701 $5.8750 C H 1%

PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Capecitabine (current access) Tab 500 mg 110,540 $211,868 $1.9167 C H 1%

PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.

Units

Cost

Unit Subsidy

DV Limit

Comments

Capecitabine (widened access) Tab 150 mg 688,630 $4,045,701 $5.8750 C H 1%

PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date. PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.

Tab 500 mg

110,540

$211,872

$1.9167

C H

Carboplatin Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml Inj 10 mg per ml, 100 ml Cyclosporin Cap 25 mg Cap 50 mg Cap 100 mg Inf 50 mg per ml, 5 ml Oral liq 100 mg per ml Doxorubicin Inj 10 mg Inj 50 mg Inj 100 mg Inj 200 mg Epirubicin Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 25 ml Inj 2 mg per ml, 50 ml Inj 2 mg per ml, 100 ml Idarubicin Hydrochloride Cap 5 mg H PCT 1% 19 H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% 18,432 $97,384 $5.2834 1,170,509 384,922 546,590 $1,392,906 $912,573 $2,591,711 $1.1900 $2.3708 $4.7416 C H C H C H H C H 1% 1% 1% 1% 1%

Bids would need to be for a microemulsion formulation. Bids would need to be for a microemulsion formulation. Bids would need to be for a microemulsion formulation.

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Idarubicin Hydrochloride Cap 10 mg Inj 5 mg Inj 10 mg Imatinib Mesylate Tab 100 mg 469,635 $18,785,400 $40.0000 H PCT 1% H PCT 1% H PCT 1% Units Cost Unit Subsidy DV Limit Comments

+ C H

Bids would be accepted for either tablets or capsules. Tender agreement may be subject to a Special Authority restriction

Irinotecan (current access) Inj 20 mg per ml, 2 ml H PCT 1%

Inj 20 mg per ml, 5 ml

H PCT 1%

Irinotecan (widened access) Inj 20 mg per ml, 2 ml H PCT 1%

Inj 20 mg per ml, 5 ml

H PCT 1%

Letrozole Tab 2.5 mg Megestrol Acetate Tab 160 mg Methotrexate Tab 2.5 mg Tab 10 mg Mycophenolate Mofetil Cap 250 mg Inj 500 mg Powder for oral liq 1 g per 5 ml Tab 500 mg 34,215 860,272 $59,099 $1,462,462 $1.7273 $1.7000 538,432 $457,667 $0.8500 C H H C H C H 1% 1% 1% 1% 1,999,584 456,729 $347,928 $373,878 $0.1740 $0.8186 C H C H 1% 1% 44,413 $85,747 $1.9307 C H 1% 478,088 $423,108 $0.8850 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Octreotide (somatostatin analogue) LAR inj 10 mg LAR inj 20 mg LAR inj 30 mg Oxaliplatin Inj 50 mg Inj 100 mg Pipobroman Tab 25 mg H PCT 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction.

Units

Cost

Unit Subsidy

DV Limit

Comments

200 1,346 996

$354,500 $1,772.5000 $3,174,878 $2,358.7500 $2,939,445 $2,951.2500

C H C H C H

1% 1% 1%

H PCT 1% H PCT 1%

Thalidomide Cap 50 mg Cap 100 mg Vinorelbine (current access) Inj 10 mg per ml, 1 ml H PCT 1%

H PCT 1% H PCT 1%

Inj 10 mg per ml, 5 ml

H PCT 1%

Vinorelbine (widened access) Inj 10 mg per ml, 1 ml H PCT 1%

Inj 10 mg per ml, 5 ml

H PCT 1%

Zoledronic Acid Inj 4 mg H 1%

Respiratory System and Allergies

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Fluticasone propionate Metered aqueous nasal spray, 50 mcg per dose 28,026,549 $3,115,618 $0.1112 C H 1%

A confidential rebate currently exists. A tender would not be implemented prior to December 2012

Units

Cost

Unit Subsidy

DV Limit

Comments

Pholcodine Oral liquid 1 mg per ml Promethazine Hydrochloride Oral liq 5 mg per 5 ml Tab 10 mg Tab 25 mg Salbutamol Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Salbutamol with Ipratropium Bromide Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Sodium Cromoglycate Nasal spray, 4% Theophylline Oral liq 80 mg per 15 ml Tab long-acting 250 mg 95,919 1,050,831 $2,973 $226,034 $0.0310 $0.2151 C H C H 1% 1% 59,247 $42,685 $0.7205 C 808,984 $173,527 $0.2145 C H 1% 350,201 888,907 $61,635 $164,448 $0.1760 $0.1850 C H C H 1% 1% 4,744,483 1,536,704 1,474,790 $147,079 $83,597 $130,961 $0.0310 $0.0544 $0.0888 C H C H C H 1% 1% 1% H 1%

Sensory Organs

Bimatoprost Eye Drops 0.03% Bimatoprost with timolol Eye Drops 0.03% with timolol 0.5% 202,675 $1,317,388 $6.5000 C H 1%

+ C H

Not currently listed on the Pharmaceutical Schedule

Brinzolamide Eye Drops 1% Chloramphenicol Eye drops 0.5% 1,898,902 $243,059 $0.1280 C H 1%

Single dose presentation would not be a DV Pharmaceutical

189,629

$370,535

$1.9540

C H

Eye oint 1% Fluorometholone Eye drops 0.1% Latanoprost Eye drops 50 mcg per ml Latanoprost with timolol Eye drops 50 mcg per ml with timolol 0.5%

555,492

$329,129

$0.5925

C H

57,213

$46,343

$0.8100

C H

586,590

$2,287,701

$3.9000

C H

+ C H

Not currently listed on the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name Line Item Sodium Hyaluronate Ophthalmic inj 14 mg per ml Ophthalmic soln 10 mg per ml Travoprost Eye drops 0.004% Travoprost with timolol Eye drops 0.004% with timolol 0.5% 95,788 $747,146 $7.8000 C H 1% H H 1% 1% Units Cost Unit Subsidy DV Limit Comments

+ C H

Not currently listed on the Pharmaceutical Schedule

Metadata

Title

2011/12 Tender Consultation - Medical Groups

Abstract

11 July 2011 2011/12 Multi-product Tender PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:   A proposal to tender certain pharmaceuticals for sole supply; and The draft process and terms and conditions…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.